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Background/Aims: Liver stiffness (LS) was assessed using 
transient elastography, and the enhanced liver fibrosis (ELF) 
test was performed to accurately assess fibrotic burden. We 
validated the LS-ELF algorithm and investigated whether the 
sequential LS-ELF algorithm performs better than concurrent 
combination of these analyses in chronic hepatitis B (CHB) 
patients. Methods: Between 2009 and 2013, 222 CHB 
patients who underwent liver biopsy (LB), as well as LS mea-
surement and the ELF test, were enrolled. Results: Advanced 
fibrosis (≥F3) and cirrhosis (F4) were identified in 141 (63.6%) 
and 118 (53.2%) patients, respectively. Areas under receiver 
operating characteristic curve for LS predictions of ≥F3 
(0.887 vs 0.703) and F4 (0.853 vs 0.706) were significantly 
higher than the ELF test (all p<0.001). Based on the LS-ELF 
algorithm, 60.4% to 71.6% and 55.7% to 66.3% of patients 
could have avoided LB to exclude ≥F3 and F4, respectively, 
whereas 68.0% to 78.7% and 63.5% to 66.1% of patients 
could have avoided LB to confirm ≥F3 and F4, respectively. 
When confirmation and exclusion strategies were applied 
simultaneously, 69.4% to 72.5% and 60.8% to 65.3% of 
patients could have avoided LB and been diagnosed as ≥F3 
and F4, respectively. The proportion of patients who cor-
rectly avoided LB for the prediction of ≥F3 (69.4% to 72.5% 
vs 42.3% to 59.0%) and F4 (60.8% to 65.3% vs 23.9% to 
49.5%) based on the sequential LS-ELF algorithm was signifi-
cantly higher than the concurrent combination (all p<0.05). 
Conclusions: The sequential LS-ELF algorithm conferred a 
greater probability of avoiding LB in CHB patients to diagnose 
advanced fibrosis and cirrhosis, and this test performed sig-
nificantly better than the concurrent combination. (Gut Liver 
2018;12:190-200)
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INTRODUCTION
Chronic hepatitis B (CHB) includes a diverse spectrum of dis-
eases, ranging from asymptomatic infection to severely fulmi-
nant hepatitis and hepatic decompensation.1,2 The extent of liver 
fibrosis is one of the main prognostic factors in CHB, which is 
correlated with the risk of developing cirrhosis and liver-related 
complications.3 Fortunately, recently developed potent antiviral 
agents for CHB can prevent disease progression, reduce the risk 
of emerging hepatocellular carcinoma (HCC), and even reverse 
hepatitis B virus (HBV)-induced liver fibrosis. However, because 
the remaining fibrotic burden cannot be completely resolved 
in most CHB patients, they are still at higher risks of develop-
ing liver-related complcations, such as HCC.3 Thus, the degree 
of liver fibrosis must be evaluated in any assessment of the risk 
of HBV-related HCC development and determination of long-
term prognosis, even in this era of potent and active antiviral 
therapy.4,5
Liver biopsy (LB) is considered a reference method for evalu-
ating the extent of liver fibrosis;6 however, it has some issues 
including sampling error and inter-/intra-observer interpre-
tational variability.7,8 In addition, LB is associated with a low 
risk of life-threatening procedure-related complications such as 
bleeding, perforation, and even death.9 Thus, various biochemi-
cal surrogates for LB, such as the FibroTest (FT), enhanced liver 
fibrosis (ELF) test, and Wisteria floribunda agglutinin-positive 
human Mac-2 binding protein,10,11 as well as physical tools such 
as transient elastography (TE) and acoustic radiation force im-
pulse elastography, have been proposed to noninvasively assess 
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the fibrotic burden in patients with chronic liver diseases.12,13
Of these noninvasive surrogates, the ELF test incorporates 
three serologic markers: hyaluronic acid (HA), N-terminal 
propeptide of collagen type III (PIIINP), and tissue inhibitor of 
metalloproteinase-1 (TIMP-1).14 The ELF test has demonstrated 
high reproducibility, automaticity, and performance in predict-
ing the extent of liver fibrosis in patients with chronic liver dis-
eases of varying etiologies.15-18 In addition, several longitudinal 
studies have reported a significant association between the ELF 
test and liver-related events, HCC, and liver-related deaths in 
patients with chronic liver diseases. Similarly, liver stiffness (LS) 
assessed using TE exhibits high accuracy and reproducibility 
in diagnosing the degree of liver fibrosis.19 Several longitudinal 
studies have demonstrated the ability of TE to predict long-term 
prognosis and assess the risk of HCC and liver-related event de-
velopment.20-22
Based on the accuracy of LS and ELF, Wong et al.23 recently 
proposed a sequential LS-ELF algorithm to diagnose advanced 
fibrosis and cirrhosis in CHB patients. An exclusion and con-
firmation strategy based on this algorithm could improve the 
diagnostic accuracy of the LS value or ELF test alone, allowing 
approximately 60% of patients to avoid LB. However, this algo-
rithm has not been validated or compared to the concurrent use 
of LS and ELF. In addition, the performance of ELF in the study 
by Wong et al.23 was relatively lower than that previously re-
ported (area under receiver operating characteristic curve [AUC], 
0.69 vs 0.86 to 0.92).15-18
Thus, in this single-center, retrospective cohort study, we in-
vestigated the diagnostic performance of LS assessed using TE 
and the ELF test for advanced fibrosis and cirrhosis, validated 
the LS-ELF algorithm, and determined whether sequential LS-
ELF algorithm is superior to their concurrent combination in 
terms of preventing unnecessary LB in CHB patients.
MATERIALS AND METHODS
1. Patients
From 2009 to 2013, 265 CHB patients who underwent TE and 
LB at Severance Hospital, Yonsei University College of Medi-
cine (Seoul, Korea) were considered eligible for inclusion in this 
study. The study population included 99 CHB patients who were 
recruited in our previous study between 2009 and 2010.14 CHB 
was defined as the persistent presence of serum HBV surface 
antigen for more than 6 months and HBV DNA positivity by 
the polymerase chain reaction assay. Before starting antiviral 
therapy, LB was performed to assess the severity of liver fibro-
sis. With informed consent, serum samples taken at the time of 
LB were stored in the Yonsei Liver Blood Bank system (approval 
number: 4-2009-0725).
The exclusion criteria were as follows: (1) measurement fail-
ure of LS value (valid shot=0); (2) unreliable LS value; (3) mea-
surement failure of the ELF test; (4) a previous history of antivi-
ral therapy and hepatic decompensation; (5) HCC at the time of 
LB or a past history of it;24 (6) liver specimen less than 15 mm 
in length; (7) alanine aminotransferase (ALT) level >5×the upper 
limit of normal (ULN); (8) co-infection with human immunode-
ficiency virus or hepatitis C virus; (9) alcohol ingestion in excess 
of 40 g/day for more than 5 years;25 and (10) heart failure or 
pregnancy (Supplementary Fig. 1). 
This study was performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki and was ap-
proved by the Institutional Review Board of Severance Hospital. 
Given its retrospective nature, written informed consent to ac-
cess clinical data was not required.
2. Histologic evaluation
LB specimens were fixed in formalin and embedded in paraf-
fin. Then standard hematoxylin and eosin and trichrome (Mas-
son) stains were performed using 4-μm sections. All of the liver 
tissue samples were evaluated by an experienced pathologist 
blinded to the patient clinical data, including the results of the 
TE and ELF tests. Liver histology was scored semi-quantitatively 
according to the Batts and Ludwig system.26 Fibrosis was staged 
(0 to 4) as follows: F0, no fibrosis; F1, portal fibrosis without 
septa; F2, portal fibrosis and few septa; F3, numerous septa 
without cirrhosis; and F4, cirrhosis.
3. ELF measurement
ELF was tested using serum samples at stored the time of 
LB. HA, PIIINP, and TIMP-1 levels were estimated using an 
ADVIA Centaur XP automated immunoanalyzer (Siemens 
Healthcare Diagnostics, Tarrytown, NY, USA). ELF was calcu-
lated by the following algorithm provided by the manufacturer: 
ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1). 
4. LS measurement using TE
At the time of enrollment, TE was performed by a well-trained 
technician (>50,000 examinations). Details of the technique and 
examination procedure were previously reported.19,27-29 LS values 
were expressed as kilopascals (kPa). The interquartile range (IQR) 
was defined as an index of intrinsic variability of LS values, 
corresponding to the interval of LS measurement results con-
taining 50% of the valid measurements between the 25th and 
75th percentiles. In this study, only LS values with 10 validated 
measurements and a 60% success rate (at minimum, both) were 
considered reliable. The median of successfully measured values 
was presumed representative of LS in a given patient only at 
IQR-to-median-value ratios <0.3.
5. Sequential LS-ELF algorithm
Wong et al.23 proposed a sequential LS-ELF algorithm, in 
which confirmation and exclusion by the LS value were per-
formed first. When the value was indeterminate, confirmation 
and exclusion by the ELF test were performed in sequence, and 
192  Gut and Liver, Vol. 12, No. 2, March 2018
when both values were nondiagnostic, LB was considered. A 
confirmatory strategy was defined as accurate if the posttest 
probability was >90%, and the exclusion strategy was defined 
as accurate if the posttest probability was <10%. The LS and 
ELF value cutoffs proposed by Wong et al.23 were adopted as 
external cutoff values in this study. The external LS value cut-
offs were as follows: ≥F3, 6.0 kPa and F4, 7.5 kPa for at least 
90% sensitivity; ≥F3, 10.2 kPa and F4, 12.0 kPa for at least 90% 
specificity; and ≥F3, 9.0 kPa and F4, 10.0 kPa for the maximum 
sum of sensitivity and specificity. Those for the ELF test were as 
follows: ≥F3, 8.4 and F4, 8.8 for at least 90% sensitivity; ≥F3, 
10.8 and F4, 11.1 for at least 90% specificity; and ≥F3, 9.8 and 
F4, 9.5 for the maximum sum of sensitivity and specificity.
6. Concurrent LS-ELF algorithm
The accuracy of the concurrent use of LS and ELF test values 
was compared to the sequential LS-ELF algorithm by Wong et 
al.’s method.23 To establish the strategy for the concurrent use 
of LS and ELF test values in our study cohort and comparing 
the accuracy of this concurrent LS-ELF algorithm with that of 
the sequential LS-ELF algorithm, we adopted two strategies 
that have been used in previous studies. First, Boursier et al.30 
proposed the concurrent combination of FibroMeter and LS val-
ues. In this algorithm, a forward binary logistic regression was 
performed using both values. Using the regression score, the 
90% negative predictive value (NPV) and 90% positive predic-
tive value (PPV) were set. LB was considered required when the 
regression score was in the indeterminate zone between the two 
thresholds. Second, Castéra et al.10 proposed a different concur-
rent combination of FT and LS values, in which LB was consid-
ered when the FT and LS values did not match. 
7. ULN of ALT and stratification according to ALT level
Because patients at the same fibrosis stage but with higher 
ALT levels tend to exhibit higher LS values, the diagnostic per-
formances of LS, ELF, and the LS-ELF algorithm were calculated 
separately according to ALT level (ALT ≤ULN and ALT 1–5× 
ULN).31 In this study, ULNs of 67 IU/L for males and 55 IU/L for 
females, as used by Wong et al.,23 were adopted. In addition, 
we used another ULN of 40 IU/L (ULNKorea) for both sexes which 
has been used in Korea.14,20,27,28 Based on ULNKorea, 218 patients 
showed an ALT level ≤5×ULN and were used for subgroup 
analyses.
8. Statistical analysis
The SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) was 
utilized for all of the statistical analysis. Data are expressed 
as medians (IQR) or number (%) as appropriate. Pearson cor-
relation coefficient was used to test the correlations among LS 
and ELF values with the other variables. The performance of 
LS and ELF in terms of predicting the degree of liver fibrosis 
was evaluated by AUCs with 95% confidence intervals (CIs). 
The DeLong method was used to compare the AUC values of 
LS and ELF. The sensitivity, specificity, PPV, NPV, positive and 
negative likelihood ratios of LS, ELF, and the LS-ELF algorithm 
were calculated to evaluate the accuracy of the determinants. 
Internal cutoffs were calculated from our study population and 
external cutoffs were from Wong et al.23 Cutoffse was defined 
as the cutoff value which had at least 90% sensitivity and 
cutoffsp was defined as the cutoff value which had at least 90% 
specificity. Cutoffse+sp was determined to maximize the sum of 
sensitivity and specificity from receiver operating characteristic 
curve analyses, and the corresponding diagnostic indices were 
calculated. The proportion of patients with correctly avoided 
biopsy was compared among the algorithms by the McNemar 
test. The cumulative incidence rate of HCC was calculated using 
the Kaplan-Meier method and compared using log-rank test. A 
value of p<0.05 was considered statistically significant. 
RESULTS
1. Patient characteristics
A total of 265 consecutive CHB patients who underwent LB, 
LS measurement, and the ELF test were considered eligible for 
this study. Fifteen patients were excluded due to measurement 
Table 1. Baseline Characteristics (n=222)
Variable Value
Demographic
    Age, yr  48 (37–55)
    Male sex 144 (64.9)
    Body mass index, kg/m2  23.7 (21.7–25.6)
    Diabetes mellitus 14 (6.3)
    Hypertension  27 (12.2)
Laboratory
    Alanine aminotransferase, IU/L 42 (30–64)
    Serum albumin, g/dL 4.2 (3.9–4.5)
    Total bilirubin, mg/dL 0.7 (0.6–0.9)
    γ-Glutamyl transpeptidase, IU/L 37 (25–69)
    Platelet count, 109/L  169 (122–201)
    HBeAg positivity 115 (51.8)
    HBV DNA, copies/mL  616,000 (19,950–14,775,000)
Histological
    Length of biopsy samples, cm 1.7 (1.6–2.0)
    Fibrosis stage
        F1/F2/F3/F4 39 (17.6)/42 (18.9)/23 (10.4)/118 (53.1)
Noninvasive fibrosis assessment
    LS value, kPa 10.2 (6.9–15.9)
    ELF test  9.7 (8.8–10.4)
Data are presented as median (interquartile range) or number (%).
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LS, liver stiff-
ness; ELF, enhanced liver fibrosis.
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Fig. 1. Receiver operating characteristic curves of liver stiffness (LS) and enhanced liver fibrosis (ELF) values to predict fibrosis stages. LS and 
ELF values were similarly predictive of ≥F2 stage (A) (area under receiver operating characteristic curve [AUC], 0.857 vs 0.802; p=0.286), whereas 
the LS value was superior to the ELF value for predicting the ≥F3 (B) (AUC, 0.887 vs 0.703; p<0.001) and F4 stages (C) (AUC, 0.853 vs 0.706; 
p<0.001). 
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Table 2. Diagnostic Indices of LS and ELF Values to Assess ≥F3 and F4 Stages according to External and Internal Cutoff Values
Variable
 ≥F3 (n=141)  F4 (n=118)
Cutoff  Sn, % Sp, % PPV, % NPV, % LR+ LR– Cutoff Sn, % Sp, % PPV, % NPV, % LR+ LR–
LS value*
    Based on external cutoff
        All
            Sn >90% 6.0 97.2 44.4 75.3 90.0 1.74 0.06 7.5 91.5 51.0 67.9 84.1 1.86 0.16 
            Sp >90% 10.2 70.2 87.7 90.8 62.8 5.68 0.33 12.0 59.3 91.3 88.6 66.4 6.85 0.44 
            Sn+Spmax 9.0 80.1 81.5 88.3 70.2 4.32 0.24 10.0 75.4 74.0 76.7 72.6 2.90 0.33 
        ALT ≤ULN
            Sn >90% 6.0 97.4 41.3 80.9 86.4 1.66 0.06 6.0 98.0 31.3 68.8 90.9 1.42 0.06 
            Sp >90% 9.0 80.3 82.6 92.2 62.3 4.61 0.23 12.0 57.6 89.1 89.1 57.6 5.26 0.47 
            Sn+Spmax 9.0 80.3 82.6 92.2 62.3 4.61 0.23 10.0 74.7 71.9 80.4 64.8 2.65 0.35 
        ALT 1–5× ULN
            Sn >90% 7.5 95.8 65.7 65.7 95.8 2.79 0.06 7.5 94.7 57.5 51.4 95.8 2.22 0.09 
            Sp >90% 12.0 58.3 97.1 93.3 77.3 20.40 0.42 12.0 68.4 95.0 86.7 86.4 13.68 0.33 
            Sn+Spmax 11.0 75.0 94.3 90.0 84.6 13.12 0.26 11.0 78.9 87.5 75.0 89.7 6.31 0.24 
    Based on internal cutoff
        All
            Sn >90% 7.6 90.8 64.2 81.5 80.0 2.53 0.14 7.6 91.5 51.0 67.9 84.1 1.86 0.16 
            Sp >90% 10.5 66.0 90.1 92.1 60.3 6.67 0.37 11.8 60.2 91.3 88.8 66.9 6.95 0.43 
            Sn+Spmax 9.0 80.1 81.5 88.3 70.2 4.32 0.24 11.0 66.1 85.6 83.9 69.0 4.58 0.39 
        ALT ≤ULN
            Sn >90% 7.5 90.6 60.9 85.5 71.8 2.31 0.15 7.6 90.9 50.0 73.8 78.0 1.81 0.18 
            Sp >90% 10.4 66.7 91.3 95.1 51.9 7.66 0.36 12.3 55.6 90.6 90.2 56.9 5.92 0.49 
            Sn+Spmax 9.0 80.3 82.6 92.2 62.3 4.61 0.23 9.0 82.8 68.8 80.4 72.1 2.65 0.24 
        ALT 1–5× ULN
            Sn >90% 8.0 91.7 68.6 66.7 92.3 2.91 0.12 8.0 94.7 57.5 51.4 95.8 2.22 0.09 
            Sp >90% 10.6 79.2 91.4 86.4 86.5 9.23 0.22 11.5 78.9 90.0 78.9 90.0 7.89 0.23 
            Sn+Spmax 10.6 79.2 91.4 86.4 86.5 9.23 0.22 11.5 78.9 90.0 78.9 90.0 7.89 0.23 
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failure of LS value, unreliable LS value, or measurement failure 
of ELF test. Of the 250 patients with valid LS values and ELF 
test results, 28 were excluded according to the exclusion crite-
ria. Finally, a total of 222 patients were selected for statistical 
analysis. 
The baseline characteristics of the study population (144 
males and 78 females) are shown in Table 1. The median age 
and body mass index was 48 years and 23.7 kg/m2, respectively. 
Histological fibrosis staging was as follows: F1 in 39, F2 in 42, 
F3 in 23, and F4 in 118 patients, respectively. The median LS 
and ELF values were 10.2 kPa and 9.7, respectively. 
2. Correlation among LS and ELF values with the other 
variables
Age, total bilirubin, γ-glutamyl transpeptidase, and fibrosis 
stage significantly increased with increasing LS and ELF val-
ues, whereas serum albumin and platelet count significantly 
decreased (all p<0.05). LS and ELF values were significantly 
correlated (r=0.500, p<0.001), whereas ALT values did not show 
significant correlations with LS or ELF values (p=0.067 and 
p=0.494, respectively) (Supplementary Fig. 1).
3. Diagnostic performance of LS and ELF values
The AUCs of LS value to predict ≥F2, ≥F3, and F4 fibrosis 
stage were 0.857 (95% CI, 0.804 to 0.900), 0.887 (95% CI, 0.837 
to 0.925), and 0.853 (95% CI, 0.799 to 0.897), respectively; and 
those of ELF were 0.802 (95% CI, 0.743 to 0.852), 0.703 (95% 
CI, 0.638 to 0.762), and 0.706 (95% CI, 0.642 to 0.765), respec-
tively (Fig. 1). The performance of the LS and ELF values to 
predict ≥F2 was statistically similar (p=0.286), whereas the LS 
Table 2. Continued
Variable
 ≥F3 (n=141)  F4 (n=118)
Cutoff  Sn, % Sp, % PPV, % NPV, % LR+ LR– Cutoff Sn, % Sp, % PPV, % NPV, % LR+ LR–
ELF test
    Based on external cutoff
        All
            Sn >90% 8.4 95.0 34.6 71.7 80.0 1.42 0.14 8.8 86.4 38.5 61.4 71.4 1.40 0.35 
            Sp >90% 10.8 24.8 92.6 85.4 41.4 3.35 0.81 11.1 21.2 91.3 73.5 50.5 2.44 0.86 
            Sn+Spmax 9.8 53.2 71.6 76.5 46.8 1.87 0.65 9.5 66.1 58.7 64.5 60.4 1.59 0.57
        ALT ≤ULN
            Sn >90% 8.4 94.9 30.4 77.6 70.0 1.36 0.18 8.8 85.9 39.1 68.5 64.1 1.40 0.36 
            Sp >90% 10.8 23.9 91.3 87.5 32.1 2.75 0.83 11.1 22.2 92.2 81.5 43.4 2.84 0.84 
            Sn+Spmax 9.8 51.3 76.1 84.5 38.0 2.14 0.64 9.5 65.7 62.5 73.0 54.1 1.50 0.54 
        ALT 1–5× ULN
            Sn >90% 9.2 75.0 48.6 50.0 73.9 1.45 0.51 9.5 68.4 52.5 40.6 77.8 1.44 0.60 
            Sp >90% 10.8 29.2 94.3 77.8 66.0 5.10 0.75 11.1 15.8 90.0 42.9 69.2 1.57 0.93 
            Sn+Spmax 9.8 62.5 65.7 55.6 71.9 1.82 0.57 9.5 68.4 52.5 40.6 77.8 1.44 0.60 
    Based on internal cutoff
        All
            Sn >90% 8.6 90.8 35.8 71.1 69.0 1.41 0.25 8.7 90.7 37.5 62.2 78.0 1.45 0.24 
            Sp >90% 10.8 24.8 92.6 85.4 41.4 3.35 0.81 10.7 28.8 91.3 79.1 53.1 3.32 0.77 
            Sn+Spmax 8.4 95.0 34.6 71.7 80.0 1.42 0.14 8.4 98.3 31.7 62.0 94.3 1.43 0.05 
        ALT ≤ULN
            Sn >90% 8.6 90.6 32.6 77.4 57.7 1.34 0.28 8.7 90.9 37.5 69.2 72.7 1.38 0.35 
            Sp >90% 10.7 25.6 91.3 88.2 32.6 2.94 0.81 10.6 31.3 90.6 83.8 46.0 3.34 0.75 
            Sn+Spmax 9.0 77.8 52.2 80.5 48.0 1.62 0.42 8.5 97.0 31.3 68.6 87.0 1.41 0.09 
        ALT 1–5× ULN
            Sn >90% 8.6 91.7 40.0 51.2 87.5 1.52 0.20 8.6 94.7 37.5 41.9 93.8 1.51 0.14 
            Sp >90% 10.8 29.2 94.3 77.8 66.0 5.10 0.75 11.1 15.8 90.0 42.9 69.2 1.57 0.93 
            Sn+Spmax 8.4 95.8 40.0 52.3 93.3 1.59 0.10 8.4 100.0 37.5 43.2 100.0 1.60 0.00 
LS, liver stiffness; ELF, enhanced liver fibrosis; Sn, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; LR, 
likelihood ratio; ALT, alanine aminotransferase; ULN, upper limit of normal.
*LS values were expressed as kilopascals (kPa).
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value was significantly superior to the ELF value in predicting 
≥F3 and F4 (both p<0.001).
Of the study population (n=222), 163 patients (73.4%) had 
ALT levels ≤ULN and 59 patients (26.4%) had ALT level of 1–5× 
ULN. If ULNKorea was used (n=218), 98 patients (45.0%) had ALT 
levels ≤ULN and 120 patients (55.0%) had ALT levels of 1–5× 
ULN. When the patients were stratified according to their ALT 
level (ALT ≤ULN vs ALT 1–5× ULN) and ULN criteria, LS value 
was significantly superior to the ELF value for predicting ≥F3 
(AUC, 0.859 to 0.910 vs 0.697 to 0.714) and F4 (AUC, 0.838 to 
0.886 vs 0.697 to 0.720) (all p<0.05) (Supplementary Table 1). 
4. Cutoff values of LS and ELF for predicting ≥F3 and F4
Diagnostic indices of LS and ELF value for predicting ≥F3 
and F4 were calculated according to external cutoff values from 
Hong Kong23 and internal cutoff values from our cohort were 
calculated (Table 2). In addition, the LS and ELF value cutoffs 
according to ALT level (ALT ≤ULN vs ALT 1–5× ULN) were de-
termined (Table 2).
For prediction of ≥F3, the internal cutoffse, cutoffsp, and 
cutoffse+sp values were 7.6, 10.5, and 9.0 kPa, respectively for 
LS; and those for ELF were 8.6, 10.8, and 8.4, respectively. An 
elevated ALT level (1–5× ULN) was associated with a slightly 
increased LS cutoff value compared to a normal ALT value 
(≤ULN) (cutoffse 7.5 kPa→8.0 kPa, cutoffsp 10.4 kPa→10.6 kPa, 
and cutoffse+sp 9.0 kPa→10.6 kPa), but was not associated with a 
change in ELF value (cutoffse 8.6→8.6, cutoffsp 10.7→10.8, and 
cutoffse+sp 9.0→8.4). For prediction of F4, an elevated ALT level 
had varying effects on LS and ELF cutoff values in predicting 
F4. Similar results were obtained when ULNKorea was used (Sup-
plementary Table 2).
5. Diagnostic performance of LS, ELF, and the LS-ELF 
algorithm 
The diagnostic performance of LS, ELF, and the LS-ELF algo-
rithm to exclude and confirm ≥F3 and F4 is shown in Table 3. 
For reference, published diagnostic indices of Wong’s cohort are 
also described in Table 3. Using a LS-ELF exclusion strategy-
based algorithm for our cohort, 60.4% (n=49) and 55.7% of 
patients (n=58) could avoid LB to exclude ≥F3 and F4 using 
external cutoffs, respectively; whereas 71.6% (n=58) and 66.3% 
(n=69) of patients could avoid LB to exclude ≥F3 and F4 using 
internal cutoffs, respectively. In addition, the proportions of pa-
tients who could avoid LB to confirm ≥F3 and F4 using exter-
Table 3. Diagnostic Performance of LS, ELF, and the LS-ELF Algorithms to Exclude and Confirm ≥F3 and F4
Variable
ELF test LS value* 
Internal External Internal External 
Exclusion strategy
    ≥F3 (n=81)
        Cutoff value 8.6 8.4 7.5 (ALT ≤ULN)
8.0 (ALT 1–5× ULN)
6.0 (ALT ≤ULN)
 7.5 (ALT 1–5× ULN)
        Sensitivity, % 91.0 95.0 90.8 97.2 
        Specificity, % 33.3 34.6 64.2 51.9 
        PPV, % 68.6 71.7 81.5 77.8 
        NPV, % 69.8 80.0 80.0 91.3 
        LR+ 1.4 1.4 2.5 2.0 
        LR– 0.3 0.1 0.1 0.1 
        No. of biopsy correctly avoided (%) 29 (35.8) 28 (34.0) 52 (64.2) 42 (51.8)
        No. of incorrect diagnosis (%) 13 (16.0) 7 (8.6) 13 (16.0) 4 (4.9)
    F4 (n=104)
        Cutoff value 8.7 8.8  7.6 (ALT ≤ULN)
8.0 (ALT 1–5× ULN)
6.0 (ALT ≤ULN)
 7.5 (ALT 1–5× ULN)
        Sensitivity, % 90.7 86.4 90.7 97.5
        Specificity, % 37.5 38.5 53.8 41.3
        PPV, % 62.2 61.4 69.0 65.3
        NPV, % 78.0 71.4 83.6 93.5
        LR+ 1.5 1.4 2.0 1.7
        LR– 0.2 0.4 0.2 0.1
        No. of biopsy correctly avoided (%) 39 (37.5) 40 (38.4) 56 (53.8) 43 (41.3)
        No. of incorrect diagnosis (%) 11 (10.5) 16 (15.3) 11 (9.3) 3 (2.8)
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nal and internal cutoffs are also summarized in Table 3. When 
ULNKorea was used, the overall results were similar (Supplementary 
Table 3).
6. Diagnostic performance of the sequential and con-
current LS-ELF algorithm to predict ≥F3 and F4
The diagnostic performances of the sequential LS-ELF algo-
rithm and concurrent LS-ELF algorithms assessed using strate-
gies by Castéra et al.10 and Boursier et al.30 to predict ≥F3 and 
F4 are shown in Table 4. When the sequential LS-ELF algorithm 
was applied using a confirmation and exclusion strategy, 69.4% 
to 72.5% and 60.8% to 65.3% of patients could avoid LB to 
diagnose ≥F3 and F4, respectively, according to internal and 
external cutoff values. The proportion of patients who could 
avoid LB to diagnose ≥F3 and F4, when the concurrent LS-ELF 
algorithm based on the strategies of Castéra and Boursier was 
applied, are also summarized in Table 4.
The proportion of patients with correctly avoided LB in 
predicting ≥F3 according to the sequential LS-ELF algorithm 
(69.4% by internal cutoffs and 72.5% by external cutoffs) was 
significantly higher than the proportion of those with correctly 
avoided LB in predicting ≥F3 according to the concurrent LS-
ELF algorithm by Castéra et al.10 (42.3% using internal cutoffs 
and 59.0% using external cutoffs) and Boursier et al.30 (57.7%) 
(all p<0.05 by McNemar test, with the exception of the bor-
derline statistical significance between Boursier’s strategy and 
the current study using external cutoff values [p=0.057]). Simi-
larly, the proportion of patients with correctly avoided LB in 
predicting F4 was significantly higher with the sequential LS-
ELF algorithm than the concurrent algorithms (all p<0.05 by 
McNemar test except for the borderline statistical significance 
between Castéra’s strategy and the current study using internal 
cutoff values [p=0.059]). When ULNKorea was used, similar find-
ings were observed (data not shown).
Table 3. Continued
Variable
ELF test LS value* 
Internal External Internal External 
Confirmation strategy
    ≥F3 (n=141)
        Cutoff value 10.8 10.8 10.5 (ALT ≤ULN)
11.0 (ALT 1–5× ULN)
9.0 (ALT ≤ULN)
 12.0 (ALT 1–5× ULN)
        Sensitivity, % 24.8 24.8 63.2 66.0 
        Specificity, % 92.6 92.6 90.0 87.8 
        PPV, % 85.4 85.4 91.0 89.6 
        NPV, % 41.4 41.4 60.4 61.7 
        LR+ 3.4 3.4 6.3 5.4 
        LR– 0.8 0.8 0.4 0.4 
        No. of biopsy correctly avoided (%) 35 (24.8) 35 (24.8) 91 (64.5) 95 (67.3)
        No. of incorrect diagnosis (%) 8 (5.6) 8 (5.6) 9 (6.3) 11 (7.8)
    F4 (n=118)
        Cutoff value 10.7 11.1 12.0 (ALT ≤ULN)
 13.0 (ALT 1–5× ULN)
12.0 (ALT ≤ULN)
 12.0 (ALT 1–5× ULN)
        Sensitivity, % 28.8 21.2 59.2 60.0 
        Specificity, % 91.3 91.3 91.2 89.5 
        PPV, % 79.1 73.5 87.7 85.7 
        NPV, % 53.1 50.5 68.0 68.0 
        LR+ 3.3 2.8 6.7 5.7 
        LR– 0.8 0.8 0.4 0.4 
        No. of biopsy correctly avoided (%) 34 (28.8) 25 (21.1) 71 (60.1) 72 (61.0)
        No. of incorrect diagnosis (%) 9 (7.6) 9 (7.6) 10 (8.4) 12 (10.1)
The accuracy of the LS-ELF algorithm using internal cutoff values is calculated from our study population. The external cutoff values describe the 
published results from the Wong’s study.23
LS, liver stiffness; ELF, enhanced liver fibrosis; ALT, alanine aminotransferase; ULN, upper limit of normal; PPV, positive predictive value; NPV, 
negative predictive value; LR, likelihood ratio.
*LS values were expressed as kilopascals (kPa).
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7. Schematic diagram of the sequential LS-ELF algorithm
A schematic diagram of the sequential LS-ELF algorithm is 
shown in Fig. 2. Using the internal cutoff values, 83 patients 
were excluded from ≥F3 (58 with correct exclusion and 25 with 
incorrect exclusion). In addition, 107 patients were confirmed 
to have ≥F3 (96 with correct confirmation and 11 with incorrect 
confirmation) (Fig. 2A). Regarding an F4 diagnosis, 87 patients 
were excluded (59 with correct exclusion and 28 with incor-
rect exclusion). Furthermore, among the 94 patients confirmed 
with F4, 86 had a correct diagnosis and eight had an incorrect 
diagnosis (Fig. 2B). Diagrams of diagnoses using external cutoff 
values to predict ≥F3 and F4 are shown in Fig. 2C and D. In 
addition, all of the diagnostic diagrams using ULNKorea showed 
similar patterns in terms of predicting ≥F3 and F4 (Supplemen-
tary Fig. 2). 
8. Prognostic value of LS-ELF algorithm
When the study population was divided into two groups ac-
cording to the combined LS-ELF algorithm using the internal 
cutoff values for prediction of ≥F3, a significantly higher inci-
dence of HCC was observed in patients with advanced fibrosis 
confirmed (n=107) than in patients with advanced fibrosis ex-
cluded (n=83) (p<0.001 by log-rank test) (Supplementary Fig. 3). 
When the internal cutoff value for prediction of F4 and external 
cutoff values for prediction of ≥F3 and F4 were used, similar 
findings were also observed (data not shown).
DISCUSSION
Although TE can accurately assess the degree of liver fibrosis, 
its diagnostic performance for detecting early stage liver fibro-
sis is unsatisfactory.19 Similarly, ELF can reliably predict the 
degree of liver fibrosis.15-18 Recently, Wong et al.23 proposed a 
sequential diagnostic algorithm using LS and ELF values, which 
was effective for avoiding LB in CHB patients. In our study, we 
found that the LS-ELF algorithm prevented unnecessary LB in 
69.4% to 72.5% of patients with advanced liver fibrosis, similar 
to the results of a Hong Kong study (61% to 66%). Moreover, 
the sequential LS-ELF algorithm was significantly superior to 
the concurrent use of two surrogates in terms of avoiding LB in 
CHB patients. 
This study had several clinical strengths. First, we validated 
the diagnostic performance of a recently proposed LS-ELF algo-
rithm. The diagnostic accuracy of LS value for predicting liver 
fibrosis was similar in our cohort and the Hong Kong study23 
(AUC, 0.857 to 0.887 vs 0.82 to 0.83), whereas the accuracy 
of the ELF test in our cohort was higher than that in the Hong 
Kong study23 (AUC, 0.703 to 0.802 vs 0.59 to 0.69). Neverthe-
less, our data demonstrated that the combined use of LS and 
Table 4. Diagnostic Performance of the Sequential and Concurrent LS-ELF Algorithms to Predict ≥F3 and F4
Variable
Sequential combination Concurrent combination
Internal cutoff External cutoff
Using Castéra’s strategy10 Using Boursier’s 
strategy30Internal cutoff External cutoff
≥F3
     Sensitivity, % 97.0 97.4 66.7 100.0 97.9
     Specificity, % 67.8 40.2 90.1 55.6 88.9
     PPV, % 81.5 63.6 92.2 79.7 93.9
     NPV, % 93.8 93.5 60.8 100.0 96.0
     LR+ 3.0 1.6 6.8 2.25 8.8
     LR– 0.0 0.1 0.4 0.00 0.0
     No. of biopsy correctly avoided (%) 154 (69.4) 161 (72.5) 94 (42.3) 131 (59.0) 128 (57.7)
     No. of incorrect diagnosis (%) 36 (16.2) 24 (10.8) 8 (3.6) 36 (16.2) 12 (5.4)
F4
     Sensitivity, % 86.4 97.2 44.9 100.0 96.6
     Specificity, % 84.6 51.9 88.5 63.5 90.4
     PPV, % 86.4 77.8 81.5 75.6 91.9
     NPV, % 84.6 91.3 58.6 100.0 95.9
     LR+ 5.6 2.0 3.9 2.7 10.0
     LR– 0.2 0.1 0.6 0.0 0.0
     No. of biopsy correctly avoided (%) 145 (65.3) 135 (60.8) 53 (23.9) 96 (43.2) 110 (49.5)
     No. of incorrect diagnosis (%)  36 (16.2)  32 (14.4) 12 (5.4) 38 (17.1) 14 (6.3)
LS, liver stiffness; ELF, enhanced liver fibrosis; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio.
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ELF values has improved diagnostic accuracy, which is consis-
tent with Wong et al.23 Because ELF shows better performance 
in predicting early stage fibrosis (≥F2) (AUC: 0.802 in our study 
and 0.82 to 0.90 in previous studies,16-18) and LS shows better 
performance in predicting advanced-stage fibrosis (≥F3) (AUC: 
0.887 in our study and 0.83 to 0.90 in previous studies,23,32) their 
combined use enhances the overall accuracy of assessment of 
fibrotic burden. Similarly, the combined use of two surrogates, 
such as the combination of FT and LS by Castéra et al.10 in CHC 
patients and the combination of FibroMeter and LS values by 
Boursier et al.,30 improves diagnostic accuracy compared to use 
of either marker alone, which supports our findings. In addition, 
we found the prognostic value of LS-ELF algorithm by showing 
the significantly higher incidence rate of HCC in patients with 
advanced fibrosis or cirrhosis confirmed than in patients with 
advanced fibrosis or cirrhosis excluded. Although validation 
studies in other ethnic groups are required, the LS-ELF algo-
rithm can be applied to CHB patients in Asian counties, which 
have a high prevalence of HBV.
Second, our study revealed that the sequential use of LS and 
ELF values is superior to their concurrent use. According to the 
sequential LS-ELF algorithm, the proportion of patients with 
correctly avoided LB in predicting ≥F3 (69.4% to 72.5% vs 
42.3% to 59.0%) and F4 (60.8% to 65.3% vs 23.9% to 49.5%) 
was significantly higher than that of concurrent use of LS and 
ELF. Although further prospective studies confirming our results 
and dealing with cost-efficiency of this diagnostic algorithm are 
required, sequential strategy may potentially lead to cost sav-
ings. That is, the concurrent use of LS value and the ELF test to 
screen all of the CHB patients incurs expenses compared to the 
sequential measurement of two surrogates. 
Third, we validated the LS-ELF algorithm in various clinical 
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Fig. 2. Prediction of ≥F3 and F4 stages using the combined LS-ELF algorithm with internal (A, B) and external cutoff values (C, D). 
LS, liver stiffness; ELF, enhanced liver fibrosis; CHB, chronic hepatitis B. 
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settings to investigate the potential influence of clinical con-
founders. To reveal whether the main results can be influenced 
according to the specific characteristics of our cohort, we tested 
the LS-ELF algorithm according to both internal and external 
cutoff values from Hong Kong23 and the different ULN of the 
ALT level between Hong Kong (67 IU/L for males and 55 IU/
L for females) and Korea (40 IU/L for both sexes). The overall 
results were not influenced by several potential confound-
ers, which supports the applicability of the LS-ELF algorithm. 
However, due to the different distribution of fibrosis stage and 
ALT level between our work and the Hong Kong study, further 
research is required.
In our study, the internal cutoff values of LS according to 
fibrosis stage were 9.0 to 11.0 kPa and those of ELF were 8.4 to 
9.8, similar to previous reports.23,25,28,29 Although the LS cutoff 
increased with increasing ALT level, LS values were not corre-
lated with ALT levels (p=0.067); therefore, ALT only had mini-
mal effects on the internal cutoff values of LS and ELF in our 
study, in contrast to previous reports.31,33-35 This might be due to 
attenuation of the influence of a high ALT level by exclusion of 
CHB patients with ALT levels >5×ULN. The LS results of CHB 
patients with acute exacerbation are not reliable for diagnosing 
cirrhosis,34 and the cutoff LS values of patients with ALT levels 
1–5× ULN were higher than those of patients with normal ALT 
levels.31,33 However, a recent multicenter study reported that the 
overestimating influence of an ALT 1–10× ULN was modest, 
as the accuracy of LS values was similar irrespective of ALT 
adjustment.35 Due to this controversy, we stratified the patients 
according to ALT level (ALT ≤ULN vs ALT 1–5× ULN) and ULN 
criteria (ULN vs ULNKorea), but ALT level had no significant ef-
fects on the results. In this study, ELF values did not correlate 
with ALT levels, and thus different ELF cutoff values according 
to ALT level could not be used.
We are aware of several issues with this study. First, because 
of its retrospective design, the study was subject to potential 
selection bias. Histological information for all of the patients 
who started antiviral therapy during the study period could not 
be obtained, despite confirming the diagnostic accuracy of the 
LS-ELF algorithm. Thus, further prospective validation of the 
LS-ELF algorithm is required before it can be applied in clinical 
practice. In addition, although we excluded patients with the 
length of liver samples <1.5 cm not only for securing more reli-
able pathological interpretation, but also for obtaining a large 
sample size as much as we could, the relatively insufficient 
quality of liver sample might have limited the accuracy of his-
tological assessment of liver fibrosis. Second, because validation 
of the LS-ELF algorithm in patients with ALT<5×ULN was re-
stricted to prevent the confounding influence of high ALT levels 
on LS values, it cannot be recommended for patients with AT 
values >5×ULN. However, most of the unusually high LS during 
acute liver injury showed a progressive and rapid decrease in 
parallel with a decrease in ALT levels.34 Thus, applicability of the 
LS-ELF algorithm after stabilizing ALT level by antiviral or con-
servative therapy should be investigated. Third, probably due to 
low NPV of exclusion strategy, our study showed higher rates 
of incorrect diagnosis of patients who avoided LB compared 
to Wong et al.23 (NPV, 69.9% to 83.1% in this work vs 90% in 
Wong’s study). Fourth, this study had a potential spectrum bias, 
with a high proportion of patients with cirrhosis (53.2%). In 
contrast, in Wong et al.,23 15% of patients had F3 fibrosis and 
25% had cirrhosis. However, despite the different fibrosis stage 
distribution between Korea and Hong Kong, the LS-ELF algo-
rithm consistently performed better than either LS or ELF alone. 
Lastly, although the sequential LS-ELF diagnostic algorithm 
exhibited enhanced overall diagnostic accuracy, it is associated 
with higher costs than LS alone. Thus, a cost-efficiency analysis 
of this algorithm is warranted.
In conclusion, the sequential LS-ELF algorithm had a higher 
probability of preventing LB in CHB patients to diagnose ad-
vanced fibrosis and cirrhosis and performed significantly bet-
ter than that of the concurrent algorithms. However, further 
prospective validation studies are required before this algorithm 
can be used clinically.
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